|
| Number | Author | Study design | Treatment regimen | Study subjects | Number of children | Treatment completion rate | Adverse event | Incidence TB | Mortality | Follow-up months | Remark |
|
| Seddon et al. [7] (2013) | Prospective cohort
South Africa | Ofloxacin, ethambutol, and high dose | Children < 5 years, CLHIV < 15 years | 186 | 75.8% (141/186) | 7/186 (3.7%) | 6/141 on PT
4/45 not on PT | 1 (0.5%) | 219 p-y (12–24 months) | - |
| Schaaf et al.
[8] (2002) | Prospective cohort
S. Africa | High dose isoniazid, pyrazinamide, ethionamide, ethambutol/ | Children < 5 years old | 41 + 64 | | 30/61 Eth
1/15 OFX | 2/41 on PT 13/64 not on PT | No deaths | 30 | - |
| Adler-Shohet et al. [9] (2014) | Prospective cohort
California | 9 mon levofloxacin and pyrazinamide | Children | 31 | 8/26 (31%)
(7 changed Rx
11 did not complete) | All children | 0 | No deaths | 24 | No separate mention on outcome in those who refused PT |
| Gracia-Prats et al. [10] (2014) | Retrospective
community cohort
S. Africa | Ofloxacin, ethambutol, and high dose | <15 years | 38 | 24/34 (71%) | No | No TB | No deaths | 12 | PT offered only to HHC < 5 years of age |
| Bamrah et al.
[11] (2014) | Prospective cohort
Micronesia | 12 mon levofloxacin and ethambutol | Children < 12 years | 119
(only 26 children) | 25/26 (95%) | Not clear | 0/104 on PT
3/15 not on PT | No deaths | 36 | Not mentioned who developed TB—adult or child |
| Feja et al.
[12] (2008) | Retrospective chart review
NYC | 9 mon quinolones, cycloserine, ethionamide, pyrazinamide, ethambutol | Children < 15 years | 51 | 36/41 (88%) at DOHMH; 2/9 (22%) | 8/22 (24%) | No TB | No deaths | 24 | No comparator group without PT |
| Attamna et al.
[13] (2009) | Retrospective chart review
Israel | Ciprofloxacin and | | 476
(387 no Rx versus 89 PT) | Not clear | Not clear | No TB in any group | Not clear | 72 | Low TB prevalence area |
|
